Search results
RSV Infection Raises Risk for Acute Cardiovascular Events
Medscape· 9 hours agoAccording to a US cross-sectional study, every fifth hospital patient with a respiratory syncytial ...
HSA approves new RSV vaccine – a breakthrough in elderly respiratory health
MSN News· 12 hours agoSINGAPORE: Singapore’s Health Sciences Administration (HSA) has given the green light to the Arexvy...
Electronic Health Record–Based Algorithm for Monitoring Respiratory Virus–Like Illness
Centers for Disease Control and Prevention· 4 hours agoIllness and death associated with seasonal respiratory syncytial virus (RSV) spikes, the SARS-CoV-2 pandemic, and occasional clusters of infection from ...
David Duchovny admits to trouble ‘reattaching’ to daughter after nearly losing her to 'horrifying' ...
Fox News via Yahoo News· 7 days ago"I'd never heard of it until my daughter got it, and it's very dangerous for infants, and she went...
Is This a Setback for Moderna?
Motley Fool via Yahoo Finance· 2 days agoInvestors have put their hopes in Moderna's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it...
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Investor's Business Daily· 2 days agoModerna stock tumbled — and then rebounded — after the Food and Drug Administration delayed its RSV...
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Zacks via Yahoo Finance· 3 days agoShares of Moderna, Inc. MRNA were down 4.4% on May 10 after the company announced that the FDA has...
Moderna says FDA delayed RSV vaccine approval to end of May
CNBC· 6 days agoModerna on Friday said the Food and Drug Administration has delayed the approval of its vaccine for...
NanoViricides CEO discusses NV-387’s broad-spectrum antiviral potential
Proactive Investors· 3 days agoNanoViricides (NYSE-A:NNVC) has released a slew of new data supporting the safety and ultra-broad...
A Novel Broad-Spectrum Antiviral with Activity Against RSV
Digital Journal· 2 days ago(NYSE Amer.:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that antiviral activity of NV-387 against RSV/A2 is strong enough to have ...